Celcuity Inc. Common Stock (CELC) is a publicly traded Healthcare sector company. As of May 21, 2026, CELC trades at $138.67 with a market cap of $6.45B and a P/E ratio of -36.79. CELC moved +7.15% today. Year to date, CELC is +35.20%; over the trailing twelve months it is +1217.75%. Its 52-week range spans $7.58 to $151.02. Analyst consensus is strong buy with an average price target of $169.88. Rallies surfaces CELC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Celcuity’s Phase 3 Trial Shows PFS Gains, FDA Sets July 17 PDUFA: Celcuity’s Phase 3 VIKTORIA-1 trial met its primary endpoint, showing statistically significant progression-free survival improvement with gedatolisib plus fulvestrant (with/without palbociclib) versus alpelisib regimens in PIK3CA-mutant HR+/HER2- advanced breast cancer. The FDA accepted its NDA for wild-type patients with a PDUFA date of July 17, 2026, while net loss widened to $52.8 million in Q1.
| Metric | Value |
|---|---|
| Price | $138.67 |
| Market Cap | $6.45B |
| P/E Ratio | -36.79 |
| EPS | $-3.79 |
| Dividend Yield | 0.00% |
| 52-Week High | $151.02 |
| 52-Week Low | $7.58 |
| Volume | 506 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-177.04M |
| Gross Margin | 0.00% |
9 analysts cover CELC: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $169.88.